Links for fulltext
     (May Require Subscription)
Supplementary

Article: Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma

TitleSurvival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma
Authors
Issue Date2013
Citation
HPB, 2013, v. 15, n. 8, p. 567-573 How to Cite?
AbstractBackground High-intensity focused ultrasound (HIFU) ablation is a non-invasive treatment for hepatocellular carcinoma (HCC). At present, data on the treatment's long-term outcome are limited. This study analysed the survival outcome of HIFU ablation for HCCs smaller than 3 cm. Patients and methods Forty-seven patients with HCCs smaller than 3 cm received HIFU treatment between October 2006 and September 2010. Fifty-nine patients who received percutaneous radiofrequency ablation (RFA) were selected for comparison. The two groups of patients were compared in terms of pre-operative variables and survival. Results More patients in the HIFU group patients had Child-Pugh B cirrhosis (34% versus 8.5%; P = 0.001). The 1- and 3-year overall survival rates of patients whose tumours were completely ablated in the HIFU group compared with the RFA group were 97.4% versus 94.6% and 81.2% versus 79.8%, respectively (P = 0.530). The corresponding 1- and 3-year disease-free survival rates were 63.6% versus 62.4% and 25.9% versus 34.1% (P = 0.683). Conclusions HIFU ablation is a safe and effective method for small HCCs. It can achieve survival outcomes comparable to those of percutaneous RFA and thus serves as a good alternative ablation treatment for patients with cirrhosis. © 2012 International Hepato-Pancreato-Biliary Association.
Persistent Identifierhttp://hdl.handle.net/10722/181647
ISSN
2015 Impact Factor: 2.918
2015 SCImago Journal Rankings: 1.586
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, TTen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorChu, SKFen_US
dc.contributor.authorJenkins, CRen_US
dc.contributor.authorChok, KSHen_US
dc.contributor.authorTsang, SHYen_US
dc.contributor.authorDai, WCen_US
dc.contributor.authorChan, ACYen_US
dc.contributor.authorChan, SCen_US
dc.contributor.authorYau, TCCen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorLo, CMen_US
dc.date.accessioned2013-03-19T03:51:26Z-
dc.date.available2013-03-19T03:51:26Z-
dc.date.issued2013en_US
dc.identifier.citationHPB, 2013, v. 15, n. 8, p. 567-573en_US
dc.identifier.issn1365-182X-
dc.identifier.urihttp://hdl.handle.net/10722/181647-
dc.description.abstractBackground High-intensity focused ultrasound (HIFU) ablation is a non-invasive treatment for hepatocellular carcinoma (HCC). At present, data on the treatment's long-term outcome are limited. This study analysed the survival outcome of HIFU ablation for HCCs smaller than 3 cm. Patients and methods Forty-seven patients with HCCs smaller than 3 cm received HIFU treatment between October 2006 and September 2010. Fifty-nine patients who received percutaneous radiofrequency ablation (RFA) were selected for comparison. The two groups of patients were compared in terms of pre-operative variables and survival. Results More patients in the HIFU group patients had Child-Pugh B cirrhosis (34% versus 8.5%; P = 0.001). The 1- and 3-year overall survival rates of patients whose tumours were completely ablated in the HIFU group compared with the RFA group were 97.4% versus 94.6% and 81.2% versus 79.8%, respectively (P = 0.530). The corresponding 1- and 3-year disease-free survival rates were 63.6% versus 62.4% and 25.9% versus 34.1% (P = 0.683). Conclusions HIFU ablation is a safe and effective method for small HCCs. It can achieve survival outcomes comparable to those of percutaneous RFA and thus serves as a good alternative ablation treatment for patients with cirrhosis. © 2012 International Hepato-Pancreato-Biliary Association.-
dc.languageengen_US
dc.relation.ispartofHPB (Oxford)en_US
dc.titleSurvival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailChu, SKF: fchu@hkucc.hku.hken_US
dc.identifier.emailJenkins, CR: cjenkins@hkucc.hku.hken_US
dc.identifier.emailChan, ACY: acchan@hku.hken_US
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityJenkins, CR=rp01583en_US
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.doi10.1111/hpb.12025-
dc.identifier.pmid23458602-
dc.identifier.scopuseid_2-s2.0-84880140260-
dc.identifier.hkuros213634en_US
dc.identifier.volumeEpub on 2012-12-04en_US
dc.identifier.isiWOS:000321581100003-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats